HC Wainwright Brokers Increase Earnings Estimates for PDSB

PDS Biotechnology Corporation (NASDAQ:PDSB) – Research analysts at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for shares of PDS Biotechnology in a report issued on Wednesday, August 26th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.11) per share for the quarter, up from their previous estimate of ($0.12). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.46) EPS, FY2027 earnings at ($0.33) EPS and FY2028 earnings at ($0.25) EPS.

A number of other research analysts also recently weighed in on PDSB. Weiss Ratings upgraded shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, PDS Biotechnology presently has an average rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Stock Performance

PDSB stock opened at $0.22 on Friday. The firm has a 50 day moving average of $0.64 and a two-hundred day moving average of $0.81. PDS Biotechnology has a 12 month low of $0.20 and a 12 month high of $1.55. The company has a market capitalization of $12.20 million, a price-to-earnings ratio of -0.34 and a beta of 1.62. The company has a quick ratio of 0.57, a current ratio of 0.57 and a debt-to-equity ratio of 2.73.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05).

Institutional Investors Weigh In On PDS Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in PDSB. Virtu Financial LLC bought a new stake in PDS Biotechnology during the fourth quarter worth approximately $25,000. Geode Capital Management LLC raised its position in shares of PDS Biotechnology by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after purchasing an additional 38,399 shares during the period. Renaissance Technologies LLC lifted its stake in shares of PDS Biotechnology by 25.0% in the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock worth $134,000 after buying an additional 44,100 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of PDS Biotechnology in the second quarter worth $91,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of PDS Biotechnology during the 2nd quarter worth $60,000. 26.84% of the stock is currently owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.